CEL-SCI Corp. has taken delivery of the new manufacturing facility for its lead drug candidate Multikine. This facility, located in the Baltimore area, will produce Multikine for use in CEL-SCI’s Phase III trial for first-line therapy of previously untreated head and neck cancer, and for manufacturing the drug upon approval. The facility cost about $22 million to build and will soon be commercially ready. Currently the facility can produce about $600 million worth of drug per year and can ...